611 Efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus: d...
611 Efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus: design of a phase 2 study
About this item
Full title
Author / Creator
Publisher
London: Lupus Foundation of America
Journal title
Language
English
Formats
Publication information
Publisher
London: Lupus Foundation of America
Subjects
More information
Scope and Contents
Contents
BackgroundAutoantibody-mediated diseases, such as systemic lupus erythematosus (SLE), are caused by pathogenic antibodies that can damage tissues or organs. Approved treatments are few and associated with limitations including suboptimal response. Nipocalimab is a novel high affinity, fully human, aglycosylated, effectorless IgG1 monoclonal antibod...
Alternative Titles
Full title
611 Efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus: design of a phase 2 study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_258a68c59baa42cda05c3c591e6296e1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_258a68c59baa42cda05c3c591e6296e1
Other Identifiers
E-ISSN
2053-8790
DOI
10.1136/lupus-2022-lupus21century.32
